Clinical Trial Update: CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating CC-99282 in combination with Rituximab given early after CAR T therapy in patients with relapsed or refractory B-cell non-Hodgkin lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• High-grade B-cell Lymphoma
• Mediastinal Large B-cell Lymphoma
• Transformed Indolent B-cell Non-hodgkin Lymphoma to Diffuse Large B-cell Lymphoma

Drugs mentioned

• CC-99282
• Rituximab (rituximab)

Snippet

Sponsor: Nathan Denlinger | Conditions: B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent | Phase 1 | Status: RECRUITING